Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 12/2012

01-12-2012 | Editorial Commentary

Pretreatment PET in breast cancer: is there a role?

Authors: Sue Chua, Ashley M. Groves

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2012

Login to get access

Excerpt

Breast carcinoma shows greater heterogeneity than the vast majority of adenocarcinomas and carries a highly variable prognosis dependent on a wide range of factors, including tumour size and stage, histological subtype, grade, hormone receptor status and a growing range of molecular abnormalities. Accurate preoperative prognostication is highly important in selecting the most appropriate individualized therapy for a particular patient, and considerable interest is now being focused on noninvasive imaging as a means to achieve this. The ability of 18F-FDG PET/CT to combine functional and anatomical data has contributed enormously to oncology [1], and in particular to the emerging field of personalized medicine [2], but it has not yet found a routine role in the preoperative assessment of breast cancer. We ask here whether this situation is likely to change. …
Literature
1.
Syed R, Bomanji J, Nagabushan N, Hughes S, Kayani I, Groves AM, et al. Impact of combined FDG PET on the management of head and neck tumour. Br J Cancer. 2005;92:1046–50.PubMedCrossRef
2.
Goh V, Engeldow A, Rodriguez-Justo M, Shastry M, Blackman G, Endozo R, et al. Assessment of primary colorectal cancer by integrated 18F-FDG PET/perfusion CT: decoupling of flow and metabolism occurs in early not late stage cancer. J Nucl Med. 2012;53:687–92.PubMedCrossRef
3.
Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.PubMedCrossRef
4.
Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics. 2007;27:S215–29.PubMedCrossRef
5.
Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26:4746–51.PubMedCrossRef
6.
Bernsdorf M, Berthelsen AK, Wielenga VT, Kroman N, Teilum D, Binderup T, et al. Preoperative PET/CT in early-stage breast cancer. Ann Oncol. 2012;23:2277–82.PubMedCrossRef
7.
Groves AM, Shastry M, Ben-Haim S, Kayani I, Malhotra A, Davidson T, et al. Defining the role of PET-CT in staging early breast cancer. Oncologist. 2012;17:613–9
8.
Vinh-Hung V, Everaert H, Lamote J, Voordeckers M, van Parijs H, Vanhoeij M, et al. Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer. Eur J Nucl Med Mol Imaging. 2012;39:1618–1627.
9.
Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess. 2007;11:iii–iv. xi–267.PubMed
10.
Blue Cross and Blue Shield Association. FDG positron emission tomography for evaluating breast cancer. TEC Bull (Online). 2003;20:1–7.
11.
Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543–50.PubMedCrossRef
12.
Aukema TS, Straver ME, Valdés Olmos RA, Vogel WV. A different role for FDG PET/CT in axillary lymph node staging in breast cancer. Eur J Nucl Med Mol Imaging. 2009;36:1896–7. Author reply 1898–99.PubMedCrossRef
13.
Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18:3495–502.PubMed
14.
15.
Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008;112:995–1000.PubMedCrossRef
16.
Bareschino MA, Schettino C, Colantuoni G, Rossi E, Rossi A, Maione P, et al. The role of antiangiogenetic agents in the treatment of breast cancer. Curr Med Chem. 2011;18:5022–32.PubMedCrossRef
17.
Hong H, Yang Y, Zhang Y, Engle JW, Barnhart TE, Nickles RJ, et al. Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging. 2011;38:1335–43.PubMedCrossRef
18.
Liu Z, Liu S, Wang F, Liu S, Chen X. Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers. Eur J Nucl Med Mol Imaging. 2009;36:1296–307.PubMedCrossRef
19.
Groves AM, Shastry M, Rodriguez-Justo M, Malhotra A, Endozo R, Davidson T, et al. 18F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:46–52.PubMedCrossRef
20.
Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, Schubert EK, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43:500–9.PubMed
21.
Semple SIK, Gilbert FJ, Redpath TW, Staff RT, Ahearn TS, Welch AE, et al. The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol. 2004;14:2038–45.PubMedCrossRef
22.
Groves AM, Wishart GC, Shastry M, Moyle P, Iddles S, Britton P, et al. Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT. Eur J Nucl Med Mol Imaging. 2009;36:416–21.PubMedCrossRef
23.
Cochet A, Generali D, Fox SB, Ferrozzi F, Hicks RJ. Positron emission tomography and neoadjuvant therapy of breast cancer. J Natl Cancer Inst Monogr. 2011;2011:111–5.PubMedCrossRef
24.
Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol. 2008;26:712–20.PubMedCrossRef
Metadata
Title
Pretreatment PET in breast cancer: is there a role?
Authors
Sue Chua
Ashley M. Groves
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2012
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-012-2216-7

Other articles of this Issue 12/2012

European Journal of Nuclear Medicine and Molecular Imaging 12/2012 Go to the issue

Original Article

Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer

Original Article

Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study

Original Article

Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide

Original Article

Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy

Original Article

Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome

Original Article

LMI1195 PET imaging in evaluation of regional cardiac sympathetic denervation and its potential role in antiarrhythmic drug treatment